Alterity CEO to present at Cantor 2026 event

Q: What is Alterity Therapeutics’ lead asset mentioned in this ATHE filing?

Alterity identifies ATH434 as its lead asset. The company states that ATH434 has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in Multiple System Atrophy and has also shown positive data in an open label Phase 2 trial in advanced MSA.

Q: What stage of development is Alterity Therapeutics’ MSA program in?

Alterity Therapeutics explains that it is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy. This follows clinically meaningful efficacy observed for ATH434 in a Phase 2 trial and positive results from an open label Phase 2 trial in participants with advanced MSA.

Q: Where is Alterity Therapeutics (ATHE) based according to this report?

Alterity Therapeutics states that it is based in Melbourne, Australia, and San Francisco, California, USA, reflecting operations in both Australia and the United States as it develops therapies for neurodegenerative diseases including Multiple System Atrophy.

Q: How can investors access ATHE’s Cantor conference presentation?

The company notes that a live and archived webcast of the Fireside Chat may be accessed on Alterity Therapeutics’ website under the Investors section, in the Events and Presentations area.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

ALTERITY THERAPEUTICS LTD (ATHE) reports that CEO David Stamler, M.D., will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on September 11, 2026 at 10:20 a.m. ET, with a live and archived webcast available via the company’s investor website.

Alterity is a clinical stage biotechnology company developing disease modifying therapies for neurodegenerative diseases, focusing on Multiple System Atrophy and related Parkinsonian disorders. The company is preparing to initiate a Phase 3 pivotal trial of its lead asset ATH434, which has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data in an open label Phase 2 trial in advanced MSA.

Key Figures

Conference date: September 11, 2026 Conference time: 10:20 a.m. ET Lead asset clinical phase: Phase 3 (preparing to initiate) +2 more

5 metrics

Conference date September 11, 2026 Scheduled date of Cantor Global Healthcare Conference 2026 Fireside Chat

Conference time 10:20 a.m. ET Time of CEO David Stamler’s Fireside Chat

Lead asset clinical phase Phase 3 (preparing to initiate) Development stage of ATH434 in Multiple System Atrophy

Completed randomized trial phase Phase 2 ATH434 showed clinically meaningful efficacy in a randomized, double-blind, placebo-controlled trial

Open label trial phase Phase 2 ATH434 reported positive data in participants with advanced MSA

Key Terms

Phase 3 pivotal trial, Multiple System Atrophy, randomized, double-blind, placebo-controlled, open label Phase 2 clinical trial, +1 more

5 terms

Phase 3 pivotal trial medical

"Alterity is preparing to initiate a Phase 3 pivotal trial in MSA"

A phase 3 pivotal trial is the large, final clinical study that tests whether a new drug or medical treatment works and is safe enough for regulators to approve it for widespread use. Think of it as the full-scale dress rehearsal before a product launches: positive results can unlock regulatory approval and big commercial upside, while failures can halt a program and significantly affect investor value.

Multiple System Atrophy medical

"developing disease modifying therapies in Multiple System Atrophy (MSA)"

A progressive neurological disorder that damages multiple areas of the nervous system, causing problems with movement, balance and involuntary functions like blood pressure and bladder control; think of it as critical wiring in the body slowly failing. Investors care because the condition defines the size and urgency of the market for treatments, influences clinical trial difficulty and regulatory risk, and can lead to high per-patient pricing but also greater development uncertainty.

randomized, double-blind, placebo-controlled medical

"demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2"

A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

open label Phase 2 clinical trial medical

"reported positive data in its open label Phase 2 clinical trial"

disease modifying treatments medical

"developing disease modifying treatments for neurodegenerative diseases"

FAQ

What event is ALTERITY THERAPEUTICS LTD (ATHE) participating in according to this 6-K?

Alterity Therapeutics states that CEO David Stamler, M.D., will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on September 11, 2026 at 10:20 a.m. ET, with access via a webcast on the company’s investor website.

When will ATHE’s Cantor Global Healthcare Conference 2026 Fireside Chat take place?

The company reports that the Fireside Chat is scheduled for Friday, September 11, 2026 at 10:20 a.m. ET in the United States, and will be available as a live and archived webcast through Alterity Therapeutics’ investor website.

What is Alterity Therapeutics’ lead asset mentioned in this ATHE filing?

Alterity identifies ATH434 as its lead asset. The company states that ATH434 has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in Multiple System Atrophy and has also shown positive data in an open label Phase 2 trial in advanced MSA.

What stage of development is Alterity Therapeutics’ MSA program in?

Alterity Therapeutics explains that it is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy. This follows clinically meaningful efficacy observed for ATH434 in a Phase 2 trial and positive results from an open label Phase 2 trial in participants with advanced MSA.

Where is Alterity Therapeutics (ATHE) based according to this report?

Alterity Therapeutics states that it is based in Melbourne, Australia, and San Francisco, California, USA, reflecting operations in both Australia and the United States as it develops therapies for neurodegenerative diseases including Multiple System Atrophy.

How can investors access ATHE’s Cantor conference presentation?

The company notes that a live and archived webcast of the Fireside Chat may be accessed on Alterity Therapeutics’ website under the Investors section, in the Events and Presentations area.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/03/2026 - 06:03 AM Accepted by SEC EDGAR 09/03/2026 - 06:01 AM

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1	Alterity to Present at Cantor Global Healthcare Conference

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alterity Therapeutics Limited

	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

Date: September 3, 2026

Exhibit 99.1

Alterity Therapeutics to Participate in a Fireside Chat at the

Cantor Global Healthcare Conference 2026

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 3 September 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on Friday, September 11, 2026 at 10:20 a.m. ET in the United States.

A link to the live and archived webcast may be accessed on Alterity Therapeutics website under the Investors section: Events and Presentations.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.

Authorization & Additional Information

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Contacts:

Investors

Elyse Shapiro

ir@alteritytx.com

Remy Bernarda

Investor Relations Advisory Solutions

ir@alteritytx.com

+1 (415) 203-6386

Media

Melissa Tempra

NWR Communications

melissa@nwrcommunications.com.au

Casey McDonald

Tiberend Strategic Advisors, Inc.

cmcdonald@tiberend.com

+1 (646) 577-8520

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases

EX-99.1 EXHIBIT 99.1 8.3 KB